Zeming Chen
University of Texas Medical Branch
4 Papers
17 Citations
Zeming Chen is an academic researcher from University of Texas Medical Branch. The author has contributed to research in topics: Internalization & MHC class I. The author has an hindex of 3, co-authored 4 publications. Previous affiliations of Zeming Chen include University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor
TL;DR: It is shown that hepatitis A virus ablates type 1 IFN responses by targeting the 3ABC precursor of its 3Cpro cysteine protease to mitochondria where it colocalizes with and cleaves MAVS, thereby disrupting activation of IRF3 through the MDA5 pathway.
331
GRB2 Interaction with the Ecotropic Murine Leukemia Virus Receptor, mCAT-1, Controls Virus Entry and Is Stimulated by Virus Binding
Zeming Chen,Andrey A. Kolokoltsov,Jia Wang,Shramika Adhikary,Marta Lorinczi,Lisa A. Elferink,Robert A. Davey,Robert A. Davey +7 more
TL;DR: A novel role for GRB2 is suggested in ecotropic MLV entry and infection by facilitating mCAT-1 trafficking and RNA interference-mediated suppression of endogenous GRB 2 resulted in a consistent and significant reduction of virus binding and membrane fusion.
17
Internalization Pathway to Diminish Antigen Presentation and CD8 þ T-cell Recognition of Melanoma
Sherille D. Bradley,Zeming Chen,Brenda Melendez,Amjad H. Talukder,Jahan Khalili,Tania G. Rodriguez-Cruz,Shujuan Liu,Mayra Whittington,Wanleng Deng,Fenge Li,Chantale Bernatchez,Laszlo Radvanyi,Michael A. Davies,P. Hwu,Gregory A. Lizee +14 more
- 01 Jan 2015
TL;DR: In melanoma, oncogenic BRAF V600E has been shown to drive the transcription of a specific gene signature that can promote multiple mechanisms of immune suppression within the tumor microenvironment as mentioned in this paper.
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
Sherille D. Bradley,Zeming Chen,Brenda Melendez,Amjad H. Talukder,Jahan Khalili,Tania G. Rodriguez-Cruz,Shujuan Liu,Mayra Whittington,Wanleng Deng,Fenge Li,Chantale Bernatchez,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu,Gregory Lizée +14 more
TL;DR: Data suggest that oncogenic activation of BRAF allows tumor cells to co-opt an evolutionarily conserved MHC-I trafficking pathway as a strategy to facilitate immune evasion, and provides further evidence to support testing therapeutic strategies combining MAPK pathway inhibition with immunotherapies in the clinical setting.